Experimental combo for rare blood cancer shows promise but trial halted early

NCT ID NCT03878199

Terminated Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stopped early, so we have limited information on how well it works or what side effects it may cause.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib and CPX-351 (a liposomal combination of two chemotherapy drugs, daunorubicin and cytarabine)
What this could lead to: If successful, this combination could offer a new treatment option for patients with advanced myeloproliferative neoplasms that have progressed to leukemia-like stages.
What could go wrong: The trial was terminated early with only 12 participants, so results are very limited. The combination may be too toxic or not effective enough, and it is unclear if it will work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLAST PHASE MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera blast phase chronic myelogenous leukemia, BCR-ABL1 positive essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM POLYCYTHEMIA VERA SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

OHSU

Portland, Oregon, 97239, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Simmons Cancer Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.